抄録
The overall efficacy of therapeutic monoclonal antibodies （mAbs） for asthma control in patients with uncontrolled eosinophilic asthma remains to be fully characterized. We conducted a meta-analysis of randomized controlled trials （RCTs） to analyze the efficacies of new therapeutic mAbs, such as anti-interleukin （IL）-13 therapies, anti-IL4/13 therapies, and anti-IL-5 therapies, compared with that of a placebo in patients with uncontrolled asthma. This meta-analysis complies with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses （PRISMA） guidelines. The primary efficacy outcome was asthma control as assessed by Asthma Control Questionnaire （ACQ） scores. Pooled estimates are presented as standardized mean differences （Std MDs） with 95% confidence intervals （CIs）. Seven RCTs of therapeutic mAbs, including anti-IL-13, anti-IL-4/13, and anti-IL-5, met the criteria for study inclusion. The overall Std MD of changes in the ACQ score was －0.31 （95% CI, －0.45 to －0.17; P＜0.0001）. These results strongly indicate that therapeutic mAbs are effective in controlling asthma in patients with uncontrolled eosinophilic asthma.
